Dublin, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Breast Cancer: HR+/HER2-" report to their offering. Ibrance's continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market. This report addresses the following questions: - Which branded therapies will have the largest impact on the HR+/HER2- breast cancer market? - What is the overall market potential for first-in-class product Ibrance? - How will competing CDK4/6 inhibitors ribociclib and abemaciclib fare following the earlier launch of Ibrance? - How will PI3K inhibitors alpelisib, buparlisib, and taselisib be positioned in the market? - When will generic and biosimilar therapies enter the market and what impact will they have on revenues? Key Topics Covered: FORECAST: HR+/HER2 BREAST CANCER - Abemaciclib - Afinitor (everolimus) - Alpelisib - Avastin (bevacizumab) - Buparlisib - Entinostat - Faslodex (fulvestrant) - Halaven (eribulin mesylate) - Ibrance (palbociclib) - Ixempra (ixabepilone) - Lynparza (olaparib) - Niraparib - Ribociclib - Talazoparib - Taselisib - Veliparib - Primary Research Methodology TREATMENT: HR+/HER2 BREAST CANCER - Primary Research Methodology - Disease Definition and Diagnosis - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends - Unmet Needs in HR+/HER - Breast Cancer EPIDEMIOLOGY: HER+/HER2 BREAST CANCER - Disease Background - Sources and Methodology - Forecast - Epidemiologist Insight - Strengths and Limitations MARKETED DRUGS: HR+/HER2 BREAST CANCER - Product profile: Afinitor - Product profile: Avastin - Product profile: Faslodex - Product profile: Halaven - Product profile: Ibrance - Product profile: Ixempra PIPELINE: HR+/HER2 BREAST CANCER - Product profile (late stage): Lynparza - Product profile (late stage): abemaciclib - Product profile (late stage): alpelisib - Product profile (late stage): buparlisib - Product profile (late stage): entinostat - Product profile (late stage): niraparib - Product profile (late stage): ribociclib - Product profile (late stage): talazoparib - Product profile (late stage): taselisib - Product profile (late stage): veliparib For more information visit http://www.researchandmarkets.com/research/2s...ast_cancer
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716